230 completed. 230 Phase 3, 38 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 230 | Completed 230 |
| Phase 2 | 38 | Completed 38 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Propionic Acid in Multiple Sclerosis Propionic acid 1000 mg capsule, Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Salzburger Landeskliniken | 101 | 2024-05-01 | 2026-09-15 |
| A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease Vatiquinone - Inherited Mitochondrial Disease | Phase 3 | Completed | PTC Therapeutics | 101 | 2022-06-22 | 2025-12-22 |
| A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV - Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 3 | Completed | Hoffmann-La Roche | 236 | 2022-05-03 | 2026-08-11 |
| An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD Divozilimab - Multiple Sclerosis | Phase 3 | Completed | Biocad | 44 | 2022-03-22 | 2025-05-23 |
| A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) TAK-771 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) | Phase 3 | Completed | Takeda | 26 | 2022-01-19 | 2026-06-24 |
| Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Completed | Celgene | 63 | 2021-11-11 | 2025-02-11 |
| IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients plasmapheresis device, Intravenous immunoglobulin - Guillain-Barre Syndrome | Phase 2 / Phase 3 | Completed | Assiut University | 81 | 2021-09-01 | 2023-04-06 |
| Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Ofatumumab, First line DMT - Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 185 | 2021-07-23 | 2026-03-03 |
| An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis BCD-132, Teriflunomide - Multiple Sclerosis | Phase 3 | Completed | Biocad | 336 | 2021-04-05 | 2024-11-25 |
| A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome Eculizumab, Placebo - Guillain-Barre Syndrome | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 57 | 2021-03-08 | 2025-09-08 |
| A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF) - Neuromyelitis Optica Spectrum Disorder | Phase 3 | Completed | Hoffmann-La Roche | 119 | 2021-03-02 | 2024-12-27 |
| Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis Nabiximols, Placebo - Spasticity in Participants With Multiple Sclerosis | Phase 3 | Completed | Jazz Pharmaceuticals | 68 | 2020-12-21 | 2023-07-20 |
| Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome ANX005, Placebo - Guillain-Barre Syndrome | Phase 3 | Completed | Annexon, Inc. | 242 | 2020-12-17 | 2025-05-29 |
| A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis CNM-Au8 - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Clene Nanomedicine | 55 | 2020-10-22 | 2023-12-08 |
| Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) Tolebrutinib, Placebo - Primary Progressive Multiple Sclerosis | Phase 3 | Completed | Sanofi | 767 | 2020-08-13 | 2026-01-07 |
| An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab Ofatumumab - Relapsing Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 562 | 2020-07-14 | 2026-04-09 |
| Plasma Exchange With Albumin in AMN Patients Albumin solution - Adrenomyeloneuropathy, Adrenoleukodystrophy | Phase 2 / Phase 3 | Completed | Pujol, Aurora, M.D. | 5 | 2020-03-09 | 2022-09-22 |
| Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab cetrizine, diphenhydramine - Multiple Sclerosis, Infusion Reaction | Phase 3 | Completed | Providence Health & Services | 19 | 2020-02-05 | 2024-03-04 |
| An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD Ravulizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 58 | 2019-12-09 | 2025-10-14 |
| Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Rituximab, Cladribine - Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 3 | Completed | Oslo University Hospital | 267 | 2019-10-16 | 2024-12-16 |
Showing 20 of 230. Sign in to see all of them.
Multiple Sclerosis (154) · Multiple Sclerosis, Relapsing-Remitting (58) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (15) · Multiple Sclerosis, Chronic Progressive (14) · Muscle Spasticity (13) · Recurrence (11) · Neuromyelitis Optica (8) · Adrenoleukodystrophy (7) · Optic Neuritis (6) · Rare Diseases (6) · Guillain-Barre Syndrome (5) · Mental Disorders (5) · Neurologic Manifestations (5) · Fatigue (4)
Nervous System Diseases (228) · Autoimmune Diseases of the Nervous System (221) · Autoimmune Diseases (220) · Immune System Diseases (220) · Demyelinating Autoimmune Diseases, CNS (202) · Pathological Conditions, Signs and Symptoms (73) · Disease Attributes (48) · Pathologic Processes (48) · Multiple Sclerosis (40) · Chronic Disease (34) · Signs and Symptoms (31) · Neurologic Manifestations (28) · Neuromuscular Diseases (24) · Peripheral Nervous System Diseases (20)
Interferon beta-1a (17) · nabiximols (14) · teriflunomide (14) · 4-Aminopyridine (13) · Glatiramer Acetate (13) · Dimethyl Fumarate (11) · Fingolimod Hydrochloride (8) · ocrelizumab (8) · Rituximab (7) · Natalizumab (6) · Interferon beta-1b (5) · arbaclofen placarbil (5) · Alemtuzumab (4) · Cladribine (4) · Immunoglobulins, Intravenous (4)
Biogen (25) · Jazz Pharmaceuticals (12) · Novartis Pharmaceuticals (9) · EMD Serono (8) · Hoffmann-La Roche (8) · Teva Branded Pharmaceutical Products R&D, Inc. (8) · Sanofi (7) · Acorda Therapeutics (6) · Biocad (5) · Bayer (4) · Genentech, Inc. (4) · Genzyme, a Sanofi Company (4) · National Center for Research Resources (NCRR) (4) · Novartis (4) · RVL Pharmaceuticals, Inc. (4)
United States (118) · Canada (78) · Germany (74) · France (70) · Poland (68) · United Kingdom (68) · Italy (60) · Spain (56) · Czechia (54) · Russia (45) · Belgium (43) · Ukraine (38) · Bulgaria (37) · Australia (34) · Israel (34)
Bettina Stubinski, MD (3) · Bonnie Faust (3) · Fernando Dangond, MD (3) · Michael Panzara, MD, MPH (3) · Andrew Blight, PhD (2) · David Jacobs, MD (2) · Giancarlo Comi, Prof (2)
PMID 25475413, PMID 27733070, PMID 33023488, PMID 25245812, PMID 26932146, PMID 30918100, PMID 31654272, PMID 31675266, PMID 31762387, PMID 32426039, PMID 32447743, PMID 32539719, PMID 32710396, PMID 33414927, PMID 34035833, PMID 34882037, PMID 35003076, PMID 36163349, PMID 36619856, PMID 37652990, PMID 37745914, PMID 39935588, PMID 40743487, PMID 42328798, PMID 42578463, PMID 15327042, PMID 23531349, PMID 24131282, PMID 26000222, PMID 26121423, PMID 26526385, PMID 27590291, PMID 28002688, PMID 28304217, PMID 28680917, PMID 28751099, PMID 28770420, PMID 28835401, PMID 30144037, PMID 31144568, PMID 32757523, PMID 33969750, PMID 34370275, PMID 34378446, PMID 35019731, PMID 35266417, PMID 35485424, PMID 36007339, PMID 36017780, PMID 36017797
2015 (9), 2009 (5), 2014 (4), 2008 (3), 2017 (3), 2019 (3), 2004 (2), 2016 (2), 2018 (2), R21HD091836 (1), U01NS045719 (1)